Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
View Patent ↗The present invention is directed to benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
1. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one.
3. The pharmaceutical composition of claim 1 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one in the form of a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
5. The pharmaceutical composition of claim 4 which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one.
6. The pharmaceutical composition of claim 4 which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one in the form of a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methoxypyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition of claim 7 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methoxypyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one.
9. The pharmaceutical composition of claim 7 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-[(6-methoxypyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one in the form of a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-isopropylpyridine-3-yl)]methylbenzo[h]quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
11. The pharmaceutical composition of claim 10 which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-isopropylpyridine-3-yl)]methylbenzo[h]quinazolin-4(3H)-one.
12. The pharmaceutical composition of claim 10 which comprises a pharmaceutically acceptable carrier and 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-isopropylpyridin-3-yl)]methylbenzo[h]quinazolin-4(3H)-one in the form of a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and rac-34trans-2-hydroxycyclohexyl]-6-{[6-(hydroxymethyl)pyridine-3-yl]methyl}benzo[h]-quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 13 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-{[6-(hydroxymethyl)pyridine-3-yl]methyl}benzo[h]-quinazolin-4(3H)-one.
15. The pharmaceutical composition of claim 13 which comprises a pharmaceutically acceptable carrier and rac-3-[trans-2-hydroxycyclohexyl]-6-{[6-(hydroxymethyl)pyridine-3-yl]methyl}benzo[h]-quinazolin-4(3H)-one in the form of a pharmaceutically acceptable salt thereof.